It is in clinical trials for the treatment of glioma.[3][4] The FDA granted orphan drug designation in 2015.
The target of Pritumumab, cell surface vimentin, has been implicated in the replication of coronavirus, specifically in Severe acute respiratory syndrome coronavirus (SARS-CoV).[5]
PTB has been proposed as a potential treatment for COVID-19 and related Viral Infections.[6]
References
^ abBabic I, Nurmemmedov E, Yenugonda VM, Juarez T, Nomura N, Pingle SC, Glassy MC, Kesari S (February 2018). "Pritumumab, the first therapeutic antibody for glioma patients". Human Antibodies. 26 (2): 95–101. doi:10.3233/HAB-170326. PMID29036806. S2CID3266191.